ProMetic Announces Positive Development for Mad Cow Disease Detection
MONTREAL, QUEBEC--(CCNMatthews - Oct. 25, 2006) - BSafE Innovations Inc. (BSafE), a joint venture company owned by ProMetic Life Sciences Inc. (TSX:PLI) and Top Meadow Farms, dedicated to veterinary applications of prion research, is delighted to announce preliminary findings from its most recent testing.
BSafE has in-licensed some veterinary applications of proprietary technologies developed by Pathogen Removal and Diagnostic Technologies Inc. ("PRDT"), a joint venture between the American Red Cross and ProMetic Life Sciences Inc. (ProMetic).
BSafE relies on the same PRDT platform technology and core competency used to develop the first human prion blood filter which just received European regulatory approval and which will be launched on a commercial scale by MacoPharma over the coming months.
Encouraged by the performance of the technology with human prions, PRDT scientists have been working on behalf of BSafE to demonstrate that the technology can be adapted to target specifically the bovine form of prions. Recent experiments have confirmed the ability of the proprietary technology to greatly enhance the sensitivity of post mortem testing for Mad Cow Disease.
Keep Reading
BSafE has in-licensed some veterinary applications of proprietary technologies developed by Pathogen Removal and Diagnostic Technologies Inc. ("PRDT"), a joint venture between the American Red Cross and ProMetic Life Sciences Inc. (ProMetic).
BSafE relies on the same PRDT platform technology and core competency used to develop the first human prion blood filter which just received European regulatory approval and which will be launched on a commercial scale by MacoPharma over the coming months.
Encouraged by the performance of the technology with human prions, PRDT scientists have been working on behalf of BSafE to demonstrate that the technology can be adapted to target specifically the bovine form of prions. Recent experiments have confirmed the ability of the proprietary technology to greatly enhance the sensitivity of post mortem testing for Mad Cow Disease.
Keep Reading
